港股异动 | 维亚生物(01873)绩后拉升逾20% 中期股东应占溢利同比增加4.28% 公司AI订单呈增长趋势

智通财经

Aug 29

智通财经APP获悉，维亚生物(01873)绩后拉升逾20%，截至发稿，涨22.32%，报2.85港元，成交额4902.75万港元。

消息面上，8月28日，维亚生物发布截至2025年6月30日止六个月中期业绩，收益8.32亿元(人民币，下同)，同比减少15.27%;股东应占溢利1.22亿元，同比增加4.28%;每股基本盈利0.06元。公告称，集团毛利率为40.8%，相较于去年同期提升了6.3个百分点，这主要得益于朗华业务结构的优化调整以及CRO业务运营效率提升、新业务板块增长所带来的贡献。国元国际此前指出，维亚生物自5年前已经布局AI制药，目前AI订单占比：AI相关订单占比达到新签订单的12%，且呈增长趋势。

国金证券表示，从医药魔方统计的全球AIDD(AI药物研发)相关交易首付额和总额Top 20的项目来看，重大交易集中发生在近5年内，总额超过500亿美元。生成式AI药企，从假设到实现，构建随时间增长的领先模型壁垒是要点。当算力与数据不构成太大掣肘，模型开发迭代进化的效率与训练经验积累的先机就至关重要。与大药企合作AI研发过程中的数据与模型构建正反馈飞轮，就将成就目前领先企业的护城河。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2563092009"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563092009\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563092009?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-29 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563092009","market":"us","top_or_hot":-1,"title":"港股异动 | 维亚生物(01873)绩后拉升逾20% 中期股东应占溢利同比增加4.28% 公司AI订单呈增长趋势","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/01873\">维亚生物</a>(01873)绩后拉升逾20%，截至发稿，涨22.32%，报2.85港元，成交额4902.75万港元。</p><p>消息面上，8月28日，维亚生物发布截至2025年6月30日止六个月中期业绩，收益8.32亿元(人民币，下同)，同比减少15.27%;股东应占溢利1.22亿元，同比增加4.28%;每股基本盈利0.06元。公告称，集团毛利率为40.8%，相较于去年同期提升了6.3个百分点，这主要得益于朗华业务结构的优化调整以及CRO业务运营效率提升、新业务板块增长所带来的贡献。国元国际此前指出，维亚生物自5年前已经布局AI制药，目前AI订单占比：AI相关订单占比达到新签订单的12%，且呈增长趋势。</p><p><a href=\"https://laohu8.com/S/600109\">国金证券</a>表示，从医药魔方统计的全球AIDD(AI药物研发)相关交易首付额和总额Top 20的项目来看，重大交易集中发生在近5年内，总额超过500亿美元。生成式AI药企，从假设到实现，构建随时间增长的领先模型壁垒是要点。当算力与数据不构成太大掣肘，模型开发迭代进化的效率与训练经验积累的先机就至关重要。与大药企合作AI研发过程中的数据与模型构建正反馈飞轮，就将成就目前领先企业的护城河。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 维亚生物(01873)绩后拉升逾20% 中期股东应占溢利同比增加4.28% 公司AI订单呈增长趋势</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 维亚生物(01873)绩后拉升逾20% 中期股东应占溢利同比增加4.28% 公司AI订单呈增长趋势\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-29 11:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1338279.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，维亚生物(01873)绩后拉升逾20%，截至发稿，涨22.32%，报2.85港元，成交额4902.75万港元。消息面上，8月28日，维亚生物发布截至2025年6月30日止六个月中期业绩，收益8.32亿元(人民币，下同)，同比减少15.27%;股东应占溢利1.22亿元，同比增加4.28%;每股基本盈利0.06元。公告称，集团毛利率为40.8%，相较于去年同期提升了6.3个百分点，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1338279.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1338279.html","article_id":"2563092009","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563092009","pubTimestamp":1756438913,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，维亚生物绩后拉升逾20%，截至发稿，涨22.32%，报2.85港元，成交额4902.75万港元。消息面上，8月28日，维亚生物发布截至2025年6月30日止六个月中期业绩，收益8.32亿元，同比减少15.27%;股东应占溢利1.22亿元，同比增加4.28%;每股基本盈利0.06元。国元国际此前指出，维亚生物自5年前已经布局AI制药，目前AI订单占比：AI相关订单占比达到新签订单的12%，且呈增长趋势。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","01873":"维亚生物","BK1141":"生命科学工具和服务"},"translate_title":"Changes in Hong Kong stocks | Viva Biotech (01873) rose by more than 20% after the results. Interim profit attributable to shareholders increased by 4.28% year-on-year. The company's AI orders showed a growth trend","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"智通财经APP获悉，维亚生物(01873)绩后拉升逾20%，截至发稿，涨22.32%，报2.85港元，成交额4902.75万港元。消息面上，8月28日，维亚生物发布截至2025年6月30日止六个月中期业绩，收益8.32亿元(人民币，下同)，同比减少15.27%;股东应占溢利1.22亿元，同比增加4.28%;每股基本盈利0.06元。公告称，集团毛利率为40.8%，相较于去年同期提升了6.3个百分点，这主要得益于朗华业务结构的优化调整以及CRO业务运营效率提升、新业务板块增长所带来的贡献。国元国际此前指出，维亚生物自5年前已经布局AI制药，目前AI订单占比：AI相关订单占比达到新签订单的12%，且呈增长趋势。国金证券表示，从医药魔方统计的全球AIDD(AI药物研发)相关交易首付额和总额Top 20的项目来看，重大交易集中发生在近5年内，总额超过500亿美元。生成式AI药企，从假设到实现，构建随时间增长的领先模型壁垒是要点。当算力与数据不构成太大掣肘，模型开发迭代进化的效率与训练经验积累的先机就至关重要。与大药企合作AI研发过程中的数据与模型构建正反馈飞轮，就将成就目前领先企业的护城河。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}